This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

12 Jul 2013

UK licence granted to new prostate cancer drug

XTANDI is a treatment option for prostate cancer patients who are resistant to first-line therapy.


The prostate cancer drug XTANDI (enzalutamide), manufactured by pharmaceutical company Astellas, has been granted a UK licence following the publication of positive clinical trial results.

Related News